Article

Integrated <i>ex vivo</i> screening and transcriptomic profiling to prioritize drug combinations for rare cancers

2026-07-29

Abstract excerpt

Discovering effective drug combinations requires testing many dose combinations across a diverse panel of tumor models. This approach is limited in rare cancers by a scarcity of cell lines and representative high-throughput models that would make exhaustive screening feasible and predictive. Patient-derived xenograft (PDX) models are genomically representative but too low-throughput for this purpose. Culturing PDX...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 39e1dc48-fc94-5535-9b69-77b91e6dfbff
DOI: 10.64898/2026.07.28.741264

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrated <i>ex vivo</i> screening and transcriptomic profiling to prioritize drug combinations for rare cancersDOI 10.64898/2026.07.28.741264Read

Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.Semantic proximity Read

<i>Ex vivo</i> to <i>in vivo</i> model of malignant peripheral nerve sheath tumors for precision oncologySemantic proximity Read

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read

<i>Ex vivo</i> drug testing in an ultra-rare sarcoma reveals therapeutic vulnerability and resistanceSemantic proximity Read

Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcomaSemantic proximity Read

A Rational Drug Combination Design to Inhibit Epithelial-Mesenchymal Transition in a Three-Dimensional MicroenvironmentSemantic proximity Read

Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapiesSemantic proximity Read

Multi-omics integration of malignant peripheral nerve sheath tumors nominates therapies based on chromosome 8q statusSemantic proximity Read

Integrative multi-omics combined with functional pharmacological profiling in patient-derived organoids identifies personalized therapeutic vulnerabilities of adult high-grade gliomasSemantic proximity Read

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read

Prioritizing Combinational Drug Screening: A Ranking System for <i>In Vitro</i> Drug Combinations in Neurofibromatosis Type 1Semantic proximity Read

Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicineSemantic proximity Read